FindTrial
Sign In

Cariprazine as adjunctive treatment in drug resistant obsessive compulsive disorder: A clinical trial

Cariprazine as adjunctive treatment in patients with drug resistant obsessive compulsive disorder: A randomized double blind placebo controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/053807
Enrollment
40
Registered
2023-06-13
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F422- Mixed obsessional thoughts and acts

Interventions

Intervention1: Adjunctive Cariprazine: Cap. CARIPRAZINE(1.5mg) 1cap OD orally along with usual treatment for 6 weeks in patients with drug resistant obsessive compulsive disorder Control Intervention1

Sponsors

Central Institute of Psychiatry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients of either sex, aged between 18- 50 years. 2.Patients fulfilling ICD 10-DCR diagnostic criteria for Obsessive Compulsive Disorder but are drug resistant. 3.Patients giving written informed consent.

Exclusion criteria

Exclusion criteria: 1.Any other major co-morbid psychiatric diagnoses (except mild to moderate depression, cut off as per HAM-D 2.Presence of an acute/unstable medical or neurological condition. 3.Pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
effectiveness of Cariprazine in treatment of patients with drug resistant OCDTimepoint: baseline, 2weeks, 4 weeks, 6 weeks—

Secondary

MeasureTime frame
change in the levels of serum IL 1Beta and TNF alpha in patients receiving Cariprazine.Timepoint: baseline, 2weeks, 4 weeks, 6 weeks—

Countries

India

Contacts

Public ContactSurjit Prasad

Central Institute of Psychiatry

surjitbhaimbbs@gmail.com8051213044

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026